SOURCE: StockCall


November 22, 2010 08:44 ET

Equity Research on Novartis AG and GlaxoSmithKline plc - Big Pharma Facing Lawsuits and Increased Regulatory Scrutiny

JOHANNESBURG, SOUTH AFRICA--(Marketwire - November 22, 2010) - offers investors comprehensive research on the drug manufacturers - major industry and has completed analytical research on Novartis AG (NYSE: NVS) and GlaxoSmithKline plc (NYSE: GSK). Register with us today at to have free access to these researches. 

Last month's settlement of a case against a major pharmaceutical company, GlaxoSmithKline plc, regarding production violations has ignited increased concern from the Food and Drug Administration. The recent case in question claimed the manufacturer carelessly packaged drugs of varying strengths, different types, broken pills and the presence of microorganisms. GlaxoSmithKline plc research report is available for free by signing up now at is an online platform where investors doing their due-diligence on the drug manufacturers - major industry can have easy and free access to our analyst research and opinions on Novartis AG and GlaxoSmithKline plc; investors and shareholders of these companies can simply register for a complimentary membership at

The egregious violations occurred almost a decade ago but the case was only settled recently. The settlement has been sufficient to spark further inquiries from the FDA as well as oversight organizations around the world. Global distribution of drugs is becoming an increasingly vital part of Big Pharma's revenues so the recent interest in scrutinizing production is a major cause for concern. Register now at to have free access to our reports on the drug manufacturers - major industry.

Big Pharma has vowed to a better job of policing itself but the FDA and similar global organizations are adamant about tightening production regulations and increasing the frequency of factory inspections. Inspection failures could lead to settlements in the hundreds of millions like the one seen this month as well as revenue losses and reduced consumer confidence. Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.
Novartis AG which saw a 10 percent surge in profit to $2.32 billion boosted by vigorous pharma and generic drug sales for Q3 2010 recently got positive news from the Food and Drug Administration (FDA) as the company's Xgeva cancer-related bone drug receives approval. Novartis AG research report is accessible for free by registering today at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information